SynthesisBMC gastroenterology2025
The impact of serum neuregulin 4 (NRG-4) levels on non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adipose Tissue Browning in MASLD and Its Molecular Mechanisms and Metabolic Crosstalk.Current obesity reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this systematic review and meta-analysis was to assess the association between serum neuregulin 4 (Nrg4) levels and non-alcoholic fatty liver disease (NAFLD).
methodsA comprehensive search was performed across Web of Science, EMBASE, Medline (PubMed), and Scopus to find all original published works in NAFLD up to March 2024. Studies were limited to case-control observational studies on humans. After removing duplicated studies, studies were screened based on predefined inclusion and exclusion criteria. The Joanna Briggs Institute checklist (JBI) was used for assessing the quality of case-control studies. The strength of the relationship was assessed by the odds ratios (ORs) and corresponding 95% confidence intervals (CIs). All statistical analyses were performed using Stata 17.0.
resultsFive case-control articles with 323 cases and 308 controls were included in the meta-analysis. The pooled mean ages were 42.6 years for the NAFLD group and 38.0 years for the control group. The pooled estimated OR between Nrg4 and NAFLD was 0.72 (95% CI: 0.67-0.77). The analysis shows that with increasing age (B: 1.381; SE: 0.732; P-value: 0.200; 95% CI: 0.771, 4.534), waist circumference (B: 0.076; SE: 0.041; P-value: 0.207; 95% CI: 0.002, 0.256) and TG levels (B: 0.0426; SE: 0.023; P-value: 0.212; 95% CI: -0.058, 0.143), the association of the Nrg4 index with incident NAFLD increased. Furthermore, the strength of the association between the Nrg4 index and incident NAFLD decreased with increasing levels of ALT (B: -0.124; SE: 0.119; P-value: 0.407; 95% CI: -0.638, 0.389) and HDL (B: -0.221; SE: 0.130; P-value: 0.232; 95% CI: -0.783, 0.340).
conclusionIn summary, the findings from this meta-analysis strongly suggest that Nrg4 exerts a protective effect against the development of NAFLD. The evidence indicates that measuring Nrg4 levels holds significant promise for facilitating the early diagnosis and prognostication of NAFLD. However, it's essential to note that further research with larger sample sizes and more accurate study designs is needed to corroborate these findings and establish the clinical utility of Nrg4 as a biomarker in the management of NAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.